货号:A140824
同义名:
秦皮甙
/ Fraxoside; Fraxetol 8-glucoside
Fraxin是一种从苦楝中提取的天然产物,通过抑制环腺苷酸磷酸二酯酶表现出抗氧化活性,能够保护内皮细胞免受氧化应激。并通过抑制 mURAT1 或 mGLUT9,部分增强高尿酸血症小鼠的尿酸排泄。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | PDE ↓ ↑ | PDE1 ↓ ↑ | PDE10A ↓ ↑ | PDE2 ↓ ↑ | PDE3 ↓ ↑ | PDE4 ↓ ↑ | PDE5 ↓ ↑ | PDE6 ↓ ↑ | 其他靶点 | 纯度 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Doxofylline | ✔ | 99+% | |||||||||||||||||
| Deltarasin |
+++
PDEδ , Kd: 38 nM |
95% | |||||||||||||||||
| 7-(2,3-Dihydroxypropyl)theophylline | ✔ | 98% | |||||||||||||||||
| Aminophylline |
+
PDE, IC50: 0.12 mM |
98+% | |||||||||||||||||
| Anagrelide HCl | ✔ | 99%+ | |||||||||||||||||
| Irsogladine | ✔ | mAChR,AChR | 99% | ||||||||||||||||
| PF-8380 |
+++
Autotaxin, IC50: 2.8 nM |
99%+ | |||||||||||||||||
| Dipyridamole | ✔ | 98% | |||||||||||||||||
| Balipodect |
++++
PDE10A, IC50: 0.3 nM |
99%+ | |||||||||||||||||
| Luteolin |
+
PDE1, Ki: 15.0 μM |
++
PDE2, Ki: 6.4 μM |
+
PDE3, Ki: 13.9 μM |
+
PDE4, Ki: 11.1 μM |
+
PDE5, Ki: 9.5 μM |
98% | |||||||||||||
| Milrinone |
++
PDE2, IC50: 5.2 μM |
++
PDE3, IC50: 2.1 μM |
ATPase | 99% | |||||||||||||||
| Pimobendan |
++
PDE3, IC50: 0.32 μM |
98% | |||||||||||||||||
| Cilostazol |
++
PDE3, IC50: 0.2 μM |
98% | |||||||||||||||||
| Fenspiride HCl |
+
PDE3, pIC50: 3.44 |
+
PDE4, pIC50: 4.16 |
99% (HPLC) | ||||||||||||||||
| (S)-(+)-Rolipram |
++
PDE4, IC50: 0.75 μM |
99% (HPLC) | |||||||||||||||||
| Apremilast |
+++
PDE4, IC50: 74 nM |
98% | |||||||||||||||||
| GSK256066 |
++++
PDE4B, IC50: 3.2 pM |
98+% | |||||||||||||||||
| Roflumilast |
++++
PDE4A1, IC50: 0.7 nM PDE4A4, IC50: 4.3 nM |
99% | |||||||||||||||||
| Rolipram |
+++
PDE4B, IC50: 130 nM |
99%+ | |||||||||||||||||
| Cilomilast |
+++
LPDE4, IC50: 100 nM HPDE4, IC50: 120 nM |
99% | |||||||||||||||||
| Avanafil |
++++
PDE5, IC50: 1 nM |
98% | |||||||||||||||||
| Vardenafil HCl Trihydrate |
++++
PDE5, IC50: 0.7 nM |
98% | |||||||||||||||||
| Tadalafil |
++++
PDE5, IC50: 1.8 nM |
98% | |||||||||||||||||
| Icariin |
++
PDE5, IC50: 0.432 μM |
98% | |||||||||||||||||
| Sildenafil | ✔ |
+++
PDE6, IC50: 33 nM |
98% | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | Fraxin, isolated from Acer tegmentosum, exert potent anti-oxidative stress action. Treatment with fraxin significantly lowered the serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in a CCl₄-induced hepatotoxicity rat model. In the fraxin-treated group, glutathione (GSH) significantly increased, while the malondialdehyde (MDA) in the liver significantly decreased. Fraxin also showed radical-scavenging activity. Fraxin protected HepG2 cells through Nrf2 pathway-dependent HO-1 expression[3]. Fraxin showed free radical scavenging effect at high concentration (0.5 mM) and cell protective effect against H2O2-mediated oxidative stress. Fraxin recovered viability of HUVECs damaged by H2O2-treatment and reduced the lipid peroxidation and the internal reactive oxygen species level elevated by H2O2 treatment[4]. Fraxin reduced LPS-induced TNF-α, IL-6 and IL-1β production in A549 cells and alleviated the LPS-induced wet/dry (W/D) weight ratio and the effects observed via histopathological examination of the lung in vivo. Furthermore, fraxin reduced the protein concentrations in the broncho-alveolar lavage (BAL) fluid and cytokine production in the sera. Fraxin played a protective role in LPS-induced lung injury by inhibiting the NF-κB and NLRP3 signalling pathways[5]. Fraxin elicited protective effects on mice with LPS-induced ARDS (Acute respiratory distress syndrome) and might be used as a drug to cure ARDS induced by Gram-negative bacterial infection[6]. |
| Concentration | Treated Time | Description | References | |
| SK-N-SH cells | 10 and 20 µM | 48 hours | Evaluate the antiviral effect of Fraxin on HSV-1 infection, results showed Fraxin inhibited HSV-1 GFP expression at 20 µM. | Antioxidants (Basel). 2021 Oct 18;10(10):1638 |
| glomerular mesangial cells (GMCs) | 20, 40, 60 μM | 24 hours | Fraxin significantly inhibited HG-induced FN and ICAM-1 expression and promoted the activation of the Nrf2 signaling pathway | Front Pharmacol. 2022 Mar 24;13:853383 |
| MNT1 cells | 20, 40, 80 μM | 24 hours | To evaluate the protective effect of Fraxin against H2O2-induced apoptosis. Results showed that Fraxin pretreatment significantly reduced the apoptosis rate induced by H2O2 and decreased nuclear pyknosis and fragmentation. | Heliyon. 2023 Aug 3;9(8):e18929 |
| MNT1 cells | 0, 40, 80, 160, 320 μM | 48 hours | To evaluate the effect of Fraxin on melanogenesis. Results showed that Fraxin treatment reduced melanin content and downregulated melanogenesis-related proteins (TYR, TYRP1, DCT, and RAB27A). | Heliyon. 2023 Aug 3;9(8):e18929 |
| MNT1 cells | 2.5 to 640 μM | 24, 48, and 72 hours | To evaluate the effect of Fraxin on MNT1 cell viability. Results showed that low concentrations of Fraxin (2.5 to 320 μM) had no significant effect on cell viability, while 640 μM Fraxin significantly reduced cell viability after 48 and 72 hours of treatment. | Heliyon. 2023 Aug 3;9(8):e18929 |
| Hep G2 cells | 1-100 μg/mL | 12 hours | To evaluate the protective effect of Fraxin against t-BHP-induced hepatotoxicity. Results showed that Fraxin significantly reduced t-BHP-induced cytotoxicity and decreased reactive oxygen species (ROS) production. | Molecules. 2017 Apr 6;22(4):587 |
| Administration | Dosage | Frequency | Description | References | ||
| Db/db mice | Diabetic nephropathy model | Oral | 25, 50, 100 mg/kg | 6 days per week for 8 weeks | Fraxin significantly improved renal dysfunction and pathological changes of renal fibrosis in diabetic db/db mice, and upregulated the expression of Cx43 and Nrf2/ARE pathway-related proteins | Front Pharmacol. 2022 Mar 24;13:853383 |
| Zebrafish | Zebrafish embryos | Treatment in culture medium | 40, 80, 160, 320 μM | Daily replacement of culture medium for 5 days | To verify the inhibitory effect of Fraxin on melanogenesis in zebrafish. Results showed that Fraxin treatment significantly reduced the density of melanin granules in the tails of zebrafish in a concentration-dependent manner. | Heliyon. 2023 Aug 3;9(8):e18929 |
| Sprague-Dawley rats | CCl4-induced hepatotoxicity model | Oral | 5, 10, 50 mg/kg | Five consecutive days | To evaluate the protective effect of Fraxin against CCl4-induced hepatotoxicity. Results showed that Fraxin significantly reduced serum AST and ALT levels, increased glutathione (GSH) levels, and decreased malondialdehyde (MDA) levels in the liver. | Molecules. 2017 Apr 6;22(4):587 |
| Mice | Reserpine-induced depressive-like disorder model | Oral | 50 mg/kg | Once daily for 10 days | To evaluate the effects of Fraxin on reserpine-induced depressive-like behaviors. The results showed that Fraxin significantly reduced immobility time in the forced swim test and tail suspension test and increased activity in the center zone in the open field test. Additionally, Fraxin decreased plasma corticosterone concentrations, reduced mRNA levels of pro-inflammatory cytokines in the hippocampus, and increased the expression of pCREB and BDNF in the hippocampus. | Front Behav Neurosci. 2021 Jun 17;15:650833 |
| Swiss albino BALB/c mice | LPS-induced cytokine storm model | Intraperitoneal injection | 120 mg/kg | Single dose, lasted for 24 hours | To evaluate the prophylactic effect of Fraxin on LPS-induced cytokine storm. Results showed that Fraxin significantly reduced the levels of IL-1β, IL-6, and TNF-α, and alleviated pathological damage in lung and kidney tissues. | Iran J Med Sci. 2024 May 1;49(5):322-331 |
| Wistar albino rats | Cisplatin-induced hepatotoxicity model | Oral | 40 mg/kg | Once daily for one week | To evaluate the protective effect of Fraxin against cisplatin-induced hepatotoxicity. Results showed that Fraxin significantly reduced oxidative stress parameters (e.g., MDA), enhanced antioxidant parameters (e.g., GSH, SOD, CAT, and GPx), and alleviated histopathological damage and inflammatory responses (e.g., TNF-α and Caspase-3 expression). | Iran J Basic Med Sci. 2020 Nov;23(11):1382-1387 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.70mL 0.54mL 0.27mL |
13.50mL 2.70mL 1.35mL |
27.00mL 5.40mL 2.70mL |
|
| CAS号 | 524-30-1 |
| 分子式 | C16H18O10 |
| 分子量 | 370.31 |
| SMILES Code | COC(C=C1C=C2)=C(O)C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)=C1OC2=O |
| MDL No. | MFCD00010093 |
| 别名 | 秦皮甙 ;Fraxoside; Fraxetol 8-glucoside; Fraxetin-8-O-glucoside |
| 运输 | 蓝冰 |
| InChI Key | CRSFLLTWRCYNNX-QBNNUVSCSA-N |
| Pubchem ID | 5273568 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place,Inert atmosphere,2-8°C |
| 溶解方案 |
DMSO: 250 mg/mL(675.11 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1